Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Puma Biotech (PBYI) Tops Q4 EPS by 15c
February 25, 2021 5:30 PM ESTPuma Biotech (NASDAQ: PBYI) reported Q4 EPS of ($0.14), $0.15 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $52.6 million versus the consensus estimate of $52.79 million.
During the fourth quarter of 2020 Puma continued to be negatively impacted by the challenges of COVID-19; however, we were pleased to be able to achieve NERLYNX revenues that were within the previously stated guidance, said Alan H. Auerbach, Chairman, Chief Executive Officer and President of Puma. Our year concluded with a number of positive clinical milestones for the Company, including the publication of ExteNET data in Clinical... More
